Interestingly, the P-glycoprotein inhibitor nilotinib was shown to significantly enhance doxorubicin’s ability to inhibit tumour xenograft growth in mice, but also increased doxorubicinol accumulation in the heart and cardiotoxicity43. Here, ABCB1 is linked to neoplasm.